PCOS, a condition impacting millions of women worldwide, gets a new name
Reevaluating the terminology for a complex health issue
PCOS a condition impacting millions of women – A long-standing health condition that affects fertility and increases diabetes risk is undergoing a significant rebranding, with experts suggesting the name change could enhance awareness and treatment. Polycystic ovarian syndrome, or PCOS, has traditionally been associated with ovarian cysts, but its effects extend far beyond the reproductive system. According to the World Health Organization (WHO), the disorder affects a substantial portion of the global population, yet remains underdiagnosed in many cases.
Researchers estimate that between 10% and 13% of women of reproductive age worldwide are impacted by PCOS. However, an astonishing 70% of those affected are unaware of their diagnosis. This disconnect has raised concerns among medical professionals, who argue that the current name fails to capture the full spectrum of the condition’s symptoms. Dr. Helena Teede, an endocrinologist and professor at Monash University in Australia, has been a leading voice in the effort to rename the disorder. As the lead author of a recent study published in the Lancet, she emphasizes the importance of clarity in medical terminology.
Expanding the understanding of PCOS
Teede, who has spent over two decades studying the condition, highlighted how the original name has perpetuated misconceptions. “For years, people have associated PCOS solely with ovarian cysts, leading to missed diagnoses and misaligned treatment approaches,” she explained. The new name, polyendocrine metabolic ovarian syndrome (PMOS), aims to reflect the multifaceted nature of the disorder. The Lancet paper, released on Tuesday, May 13, 2026, proposes this shift to better align the condition with its broader implications.
“By calling this condition polycystic ovary, we’re missing the big picture,” said Dr. Alla Vash-Margita, associate professor of obstetrics, gynecology, and reproductive sciences at Yale University. “The old name fostered stigma and myths, such as the belief that all patients have large cysts, which isn’t always the case.”
The renaming initiative builds on decades of research revealing the condition’s far-reaching effects. Initially viewed as a reproductive issue, PCOS has been linked to a range of metabolic complications, including insulin resistance, liver disease, and heart conditions. Dr. Andrea Dunaif, professor of medicine at the Icahn School of Medicine at Mount Sinai in New York, noted that the syndrome’s complexity became evident in the 1980s. “At first, it was recognized for its role in menstrual irregularities and fertility challenges,” she stated. “Later, studies showed it also contributes to insulin resistance, which can lead to diabetes if left unaddressed.”
Dunaif’s insights underscore how the condition has evolved in scientific understanding. “The term ‘polyendocrine’ in PMOS highlights its connection to hormonal imbalances across multiple systems,” she added. This change is intended to emphasize the metabolic component, which is now considered central to the syndrome’s classification. The new designation also acknowledges other symptoms such as sleep apnea, depression, anxiety, and body dysmorphia, which have emerged as critical aspects in recent studies.
Global collaboration and the journey to a new name
The effort to redefine the condition has spanned 14 years and involved collaboration from over 50 organizations. The Lancet paper, which marks the culmination of this work, advocates for a name that better represents the syndrome’s impact on both reproductive and metabolic health. “This shift is about reframing the conversation and ensuring PMOS is recognized as a long-term, complex condition,” said Rachel Morman, Chair of Verity PCOS UK. “It’s not just a gynecological issue—it’s a systemic disorder that affects multiple organs and functions.”
While the new name addresses many of the condition’s characteristics, some experts believe it could benefit from further refinement. Dunaif pointed out that the term might still fall short of capturing the latest research, particularly regarding the metabolic aspects. She noted that family histories suggest the syndrome can affect individuals even without ovarian cysts. “The metabolic component is now a defining feature, and the name should reflect that more clearly,” she said. “Breaking it into subtypes could help differentiate between those with primary reproductive symptoms and those with metabolic manifestations.”
Broader implications for patient care
The proposed name change is expected to influence how the condition is approached in clinical settings. Physicians in gynecology have long taken PMOS seriously, but the broader implications require input from other specialties. “The syndrome impacts not just reproductive health but also metabolic and psychological well-being,” Dunaif added. “This means we need a more integrated approach to diagnosis and treatment across medical disciplines.”
Teede emphasized that the new name could help reduce stigma and improve public perception. “Many women feel dismissed or misunderstood when their symptoms are attributed to a simple reproductive disorder,” she said. “A more accurate name can encourage proactive care and research into the condition’s diverse effects.” The transition to PMOS is also seen as a step toward raising awareness of its association with cognitive decline, as recent studies have linked metabolic syndrome to early dementia risks. This connection highlights the syndrome’s potential long-term impact on overall health.
Looking ahead: A unified approach to managing PMOS
With the name change, the hope is to unify the medical community’s focus on the syndrome’s comprehensive effects. “This is not just about renaming—it’s about fostering collaboration among specialties,” said Dr. Dunair, one of the researchers involved in the study. “From endocrinology to psychiatry, every field has a role in addressing PMOS effectively.”
As the debate over terminology continues, the shift to PMOS represents a critical moment in redefining how the condition is understood and managed. By highlighting its metabolic and endocrine components, the new name aims to ensure that PMOS is treated with the urgency and seriousness it deserves. With global recognition and ongoing research, the medical community is poised to take a more holistic approach to supporting those affected by this widespread disorder.
